Immunomodulatory progenitor cell therapy - Celixir

Drug Profile

Immunomodulatory progenitor cell therapy - Celixir

Alternative Names: Heartcel; iMP cell therapy - Celixir

Latest Information Update: 07 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cell Therapy Limited
  • Developer Celixir
  • Class Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action CD antigen modulators; CD45 antigen modulators; Cell replacements; Epidermal growth factor receptor modulators; Immunomodulators; Major histocompatibility complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiomyopathies
  • Phase II Heart failure

Most Recent Events

  • 07 Jun 2017 Phase-III clinical trials in Cardiomyopathy in Europe (Intracardiac) (Celixir pipeline, June 2017)
  • 07 Jun 2017 Celixir plans a phase II trial for Mucocutaneous lymph node syndrome (Celixir pipeline, June 2017)
  • 05 Aug 2016 Celixir, TMC Life Sciences Berhad and Thomson Medical enter into partnership to develop immunomodulatory progenitor cell therapy in Malaysia and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top